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Stein Harald Johnsena,c, Geir Bråthend,e, Dag Aarslandf,g,i and Tormod Fladbyi,j
aDepartment of Neurology, University Hospital of North Norway, Tromsø, Norway
bDepartment of Psychology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway
cDepartment of Clinical Medicine, Brain and Circulation Research Group, UiT The Arctic University
of Norway, Tromsø, Norway
dDepartment of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences,
Norwegian University of Science and Technology, Trondheim, Norway
eDepartment of Neurology and Clinical Neurophysiology, University Hospital of Trondheim, Trondheim, Norway
f Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway
gDepartment of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience,
King’s College London, London, UK
hDepartment of Psychology, University of Oslo, Oslo, Norway
iDepartment of Neurology, Akershus University Hospital, Lørenskog, Norway
jInstitute of Clinical Medicine, Campus Ahus, University of Oslo, Oslo, Norway
Handling Associate Editor: Frank Jessen
Accepted 21 August 2017
Abstract.
Background: Cognitive assessment is essential in tracking disease progression in AD. Presently, cohorts including preclinical
at-risk participants are recruited by different means, which may bias cognitive and clinical features. We compared recruitment
strategies to levels of cognitive functioning.
Objective: We investigate recruitment source biases in self-referred and memory clinic-referred patient cohorts to reveal
potential differences in cognitive performance and demographics among at-risk participants.
Methods: We included 431 participants 40–80 years old. Participants were classified as controls (n = 132) or symptom group
(n = 299). The symptom group comprised of subjective cognitive decline (SCD, n = 163) and mild cognitive impairment
(MCI, n = 136). We compared cognitive performance and demographics in memory clinic-referrals (n = 86) to self-referred
participants responding to advertisements and news bulletins (n = 179). Participants recruited by other means were excluded
from analysis (n = 34).
Results: At symptom group level, we found significant reductions in cognitive performance in memory clinic-referrals
compared to self-referrals. However, here reductions were only found within the MCI group. We found no differences in
cognitive performance due to recruitment within the SCD group. The MCI group was significantly impaired compared to
controls on all measures. Significant reductions in learning, and executive functions were also found for the SCD group.
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Conclusion: Regardless of recruitment method, both the SCD and MCI groups showed reductions in cognitive performance
compared to controls. We found differences in cognitive impairment for memory clinic-referrals compared to self-referrals
only within the MCI group, SCD-cases being equally affected irrespective of referral type.
Keywords: Alzheimer’s disease, cognitive dysfunction, mild cognitive impairment, patient recruitment, research subject
recruitment, sampling studies, subjective cognitive decline
INTRODUCTION
Mild cognitive impairment (MCI) is associated
with an increased risk for Alzheimer’s disease (AD).
MCI due to AD constitutes a transitory phase between
normal cognitive function and dementia [1]. Research
efforts have aimed to define features and trajecto-
ries of MCI due to AD to predict conversion from
MCI to AD, and to distinguish MCI due to AD from
other causes of MCI such as vascular disease, early
frontotemporal dementia, or early stages of dementia
with Lewy bodies [1, 2]. Converging evidence from
studies of at-risk cohorts and clinically normal older
individuals now indicate that the pathophysiologi-
cal underpinnings of AD may begin 10 to 15 years
before the emergence of clinical symptoms [3]. Con-
sequently, this has led to the proposal that AD has a
preclinical phase wherein brain-compensatory mech-
anisms make up for early pathological changes [4].
Identifying individuals at risk for AD in the preclini-
cal phase is a key objective [5, 6]. Future effective
treatments at this level could serve to preserve or
delay onset of objective cognitive decline [4, 7, 8].
A proposed target population for preclinical AD
is patients with subjective experience of cogni-
tive deficits, hypothesizing that subjective cognitive
decline (SCD), i.e., with normal performance on
standardized cognitive tests, may imply risk for con-
version to MCI and ultimately AD dementia [6].
SCD manifests before the onset of clinical identifi-
able impairment, such as objective cognitive decline
and could potentially serve as a target population for
early intervention trials. Indeed, several longitudi-
nal studies have shown that SCD carries a small, but
detectable risk of conversion to MCI [9–11]. A recent
systematic review of subjective cognitive complaints
(SCC) risk to AD/MCI progression reported that 16
out of 17 studies showed a 1.5- to 3-fold higher risk of
progression in patients 59 years or older [12]. How-
ever, it should also be noted that the overwhelming
majority of studies did not show progression from
SCC to objective cognitive decline (MCI or Demen-
tia) when assessed at follow-up. Bassett and Folstein
[13] have shown that up to 43% of those aged between
65 and 74 years report subjective memory problems,
while dementia prevalence in this age range is low.
Thus, in many cases, the experience of cognitive
decline is either benign, or caused by other condi-
tions or disorders than AD. Consequently, there is
a need to identify the characteristics of SCD due to
AD and other disorders, in order to identify preclini-
cal at-risk populations eligible for early intervention
and intervention trials [6].
In order to improve on research criteria for SCD,
The Subjective Cognitive Decline working group
(SCD-I) [6] have proposed a conceptual framework
for research on SCD as a preclinical risk factor for
AD. Among several issues, they underline that dif-
ferences in research setting, design, and participant
selection may influence the composition of clinical
characteristics within at-risk cohorts. Cohorts includ-
ing at-risk participants are recruited by different
means, which lead to inclusion of cohorts with dif-
ferent clinical and demographic characteristics. It has
been demonstrated that MCI participants recruited
through memory clinics harbor more AD-type pathol-
ogy [14], show a higher prevalence of APOE 4 alle-
les [15], are cognitively more impaired [15], and have
higher risk of progression to dementia [16, 17] than
participants recruited through community or popu-
lation based samples. Moreover, volunteer sample
controls have shown to be better educated and per-
form better on cognitive tests than population-based
samples [15]. However, few studies have investigated
the effects of recruitment bias in patients with SCD
[18]. Chen et al. [19] recently demonstrated that per-
sons with normal cognitive scores at baseline, showed
an annual conversion rate to MCI of 30% in a memory
clinic sample compared to 5% in a community based
sample. They attribute this finding to level of concern
leading to medical help seeking within the memory
clinic sample. Similarly, Perrotin et al. [20] recently
published findings demonstrating reduced gray
matter volumes and increased depressive symptoma-
tology in SCD cases from a memory clinic sample
compared to community-sample. These studies did
not demonstrate any differences in cognitive perfor-
mance at baseline due to recruitment bias. In contrast,
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Abdelnour et al. [21] recently showed reduced cogni-
tive performance in SCD cases from a memory-unit
compared to cases recruited from an open house
initiative offering free examinations to the commu-
nity. These findings demonstrate a need to explore
potential differences in clinical characteristics within
and between preclinical cohorts employing different
recruitment strategies. SCD is a particularly vulner-
able clinical group, as many cases ultimately are not
related to AD pathology [12, 13, 22].
This study compares cognitive performance and
demographic characteristics between at-risk par-
ticipants recruited through memory clinics and
participants self-referred by voluntary response to
news-bulletins and advertisement. We hypothesize
that participants recruited through referrals by a
general practitioner (GP) to memory outpatient clin-
ics are more cognitively impaired than participants
that are self-referred by voluntary response to news-
bulletins or advertisement. We further explore these
cohorts by comparing the cognitive symptom groups
MCI and SCD to a control group.
METHODS
This study was a part of “Dementia Disease Initi-
ation” (DDI), a co-operation between all Norwegian
health regions and university hospitals. Between
January 2013 and January 2017, we recruited par-
ticipants with self-reported cognitive reduction and
healthy controls. For further description of the DDI
cohort and methods, see Fladby et al. [23]. All
participants were examined following a standard pro-
tocol. Participants were recruited from two main
sources: 1) self-referred, following advertisements
in media, newspapers, or news bulletins, or 2) GP
referrals to local memory clinics. Additionally, cogni-
tively healthy controls were included from spouses of
patients with dementia/cognitive disorder, and from
patients who completed lumbar puncture for orthope-
dic surgery. Participants were classified as controls,
SCD or MCI according to criteria based on a com-
prehensive assessment program (see below) [6, 24].
The controls were further classified as having either
normal or abnormal cognitive screening, and with
or without first-degree relative with dementia. We
included individuals with a native language of Nor-
wegian, Swedish, or Danish. In order to capture
individuals in the preclinical, as well as predemen-
tia phases of AD, we included participants between
40 and 80 years of age. Exclusion criteria were
brain trauma or disorder, including clinical stroke,
dementia, severe psychiatric disorder, severe somatic
disease that might influence the cognitive func-
tions, or intellectual disability or other developmental
disorders.
A case report form developed for DDI [23]
included assessment protocol for SCD (see below),
medical history from participant and informant, phys-
ical and neurological examinations, as well as the
15-item Geriatric Depression Score (GDS) [25].
Educational levels were classified in the following
categories [26]: 0 = Primary school (7–8 y), 1 = High
School (9–11 y), 2 = College (12 y), 3 = Bachelor
degree (13–15 y), 4 = Master or equivalent = 16 –
17 y, 5 = Higher university degree/PhD (18–20 y).
The cognitive examination included the Mini-Mental
State Examination (MMSE-NR) [27], non-verbal
cognitive screening (The clock drawing test) [28],
verbal memory (CERAD word list) [29], visuoper-
ceptual ability (VOSP silhouettes) [32], psychomotor
speed and divided attention (Trail making A and B),
and word fluency (COWAT) [30].
The regional medical research ethics committee
approved the study. All participants gave their written
informed consent before taking part in the study. All
further study conduct was in line with the guidelines
provided by the Helsinki declaration of 1964 (revised
2013) and the Norwegian Health and Research Act.
Classification of SCD and MCI
The DDI case report form [23] includes a com-
prehensive account of participants’ experience of
subjective cognitive decline modelled on the sug-
gested framework by the working group of SCD-I.
It includes the nature of cognitive decline (cogni-
tive domain, onset), concerns and worries, including
feeling worse compared to age matched peers, and
informant confirmation of decline (when available).
Participants were classified as SCD according to the
SCD-I framework, which requires normal objective
cognitive performance in combination with subjec-
tively experienced decline in any cognitive domain
[6]. MCI was classified according to the NIA-AA
criteria which require presence of subjective cog-
nitive decline or impairment combined with lower
performance than expected in one or more cognitive
domains, yet preserved independence in functional
ability and not fulfilling the criteria of dementia
[24, 31]. Performance was classified as normal or
abnormal according to published norms (adjusted for
age, sex, and educational effects) for the different
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tests [27–30, 32–34]. Due to overlapping and mutu-
ally exclusive criteria, the cut-off values for SCD
versus MCI (defined as normal or abnormal cogni-
tion) were ≤1.5 standard deviation below normative
mean on either CERAD word list (delayed recall),
VOSP silhouettes, TMT-B or COWAT, or having
MMSE score equal to or below 27. Cognitive func-
tioning was also assessed by the Clinical Dementia
Rating scale (CDR) [35]. Participants with dementia
were excluded if CDR > 0.5 [36].
Participants
Of 577 participants considered, 87 were excluded
because they withdrew before finishing the assess-
ment program or did not fulfil the inclusion criteria.
Of the 490 participants included, 463 were classified
according to disease stage at the time of analy-
sis (Fig. 1). Participants were classified as normal
control (n = 132, mean age = 60.4, SD = 9.3) or cog-
nitive symptom group (n = 299, mean age = 63.7,
SD = 9.4), the latter comprising of symptom sub-
groups MCI (n = 136, mean age = 65.4, SD = 9.8) and
SCD (n = 163, mean age = 62.3, SD = 8.9). Partici-
pants who were recruited as normal controls, but had
abnormal cognitive screening were excluded from
analysis (n = 32). Following advertisements in media,
we recruited 179 self-referred participants (mean
age = 64.4, SD = 9.7), whereas 86 participants (mean
age = 61.5, SD = 9.1) were recruited among referrals
to local memory clinics. Participants recruited by
other means or when recruitment source was not
available were excluded from analysis (n = 34) [23].
Statistical analysis
For variables with assumed normal distribution
(age at inclusion, CERAD word list learning & recall,
T-score, VOSP silhouettes T-score, TMT A & B T-
score, and COWAT T-score), we compared means for
the different groups with one-way ANOVA (anal-
ysis of variance) and calculated effect sizes using
eta squared (ηp2). We assessed normality by visual
inspection of frequency distributions, Q-Q-plots, and
box-plots. Assessing variables with Levene’s test,
equal variance was assumed for all variables except
CERAD word list delayed recall and VOSP silhou-
ettes T-score. Continuous variables with non-normal
distribution (MMSE, Clock drawing test) were com-
pared with Mann-Whitney U tests. Education level,
being an ordinal variable, was also tested with
Mann-Whitney U. We used the Mann-Whitney U
Fig. 1. A total of 463 participants were classified according to dis-
ease stage at the time of analysis, whereof 32 recruited as controls
showed abnormal cognitive performance and were excluded from
analysis. Participants were classified as belonging to a normal con-
trol group or cognitive symptom group (SCD and MCI), and their
characteristics analyzed depending on recruitment source.






We compared the binary variable “sex”, with Pear-
son’s Chi square test. All analyses were performed
in the Statistical Package for Social Sciences (SPSS)
version 24.
RESULTS
Cognitive performance compared to recruitment
strategy
All data pertaining to comparisons of cogni-
tive performance to recruitment strategies, including
demographic characteristics, are shown in Table 1.
No differences in gender distributions were shown
between recruitment sources. However, at symp-
tom group level, including both SCD and MCI
participants, memory clinic-referrals were shown to
be both younger (p < 0.05, ηp2 = 0.020) and less
educated (p < 0.01, r = 0.160) than self-referrals.
When measuring the SCD and MCI groups sep-
arately, this recruitment bias was only shown
for memory clinic-referred MCI participants [age
(p < 0.001, ηp2 = 0.089) and education level (p < 0.05,
r = 0.201)]. We found no differences in demographic
characteristics between recruitment strategies within
the SCD group.
At symptom group level, including both SCD and
MCI participants, memory clinic-referrals performed
significantly worse than self-referrals on MMSE
(p < 0.05, r = 0.138), Clock drawing test (p < 0.01,
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Table 1
Demographic characteristics and cognitive test results comparisons between recruitment strategies within the cognitive symptom group
(MCI and SCD) and symptom subgroups mild cognitive impairment (MCI) and subjective cognitive decline (SCD)
Cognitive symptom Group
(MCI & SCD) MCI SCD
Self-referral Memory Self-referral Memory Self-referral Memory
clinic referral clinic referral clinic referral
Age at inclusion n = 179 n = 86 n = 69 n = 46 n = 110 n = 40
Mean (SD) 64.4 (9.7) 61.5 (9.1) 67.4 (9.3) 61.3 (10.3) 62.5 (9.6) 61.7 (7.7)
p < 0.05a p < 0.001a p = n.s.a
ηp2 = 0.020 ηp2 = 0.089
Female/Total 96/179 45/86 33/69 21/46 63/110 24/40
Percentage female 53.6% 52.3% 47.8% 45.7% 57.3% 60.0%
p = n.s.c p = n.s.c p = n.s.c
Education level n = 178 n = 86 n = 68 n = 46 n = 110 n = 40
Median (IQR) 3.0 (2.0) 2.5 (2.0) 3.0(2.0) 2.5 (2.0) 3.0 (2.0) 2.5 (2.75)
p < 0.01b p < 0.05b p = n.s.b
r = 0.160 r = 0.201
MMSE n = 178 n = 85 n = 69 n = 45 n = 109 n = 40
Mean (SD) 28.7 (1.5) 28.1 (1.9) 28.0 (1.8) 27.3 (2.2) 29.2 (1.1) 29.1 (1.0)
p < 0.05b p = n.s.b p = n.s.b
r = 0.138
Clock Drawing Test n = 178 n = 84 n = 69 n = 45 n = 109 n = 39
Mean (SD) 4.9 (0.4) 4.7 (0.6) 4.8 (0.5) 4.6 (0.8) 4.9 (0.3) 4.8 (0.4)
p < 0.01b p < 0.05b p = n.sb
r = 0.188 r = 0.186
CERAD word list Learning T score n = 177 n = 84 n = 68 n = 45 n = 109 n = 39
Mean (SD) 49.7 (12.0) 43.5 (14.5) 43.1 (12.7) 36.0 (12.4) 53.8 (9.6) 52.1 (11.7)
p < 0.001a p < 0.01a p = n.s.a
ηp2 = 0.049 ηp2 = 0.073
CERAD word list Recall T-score n = 176 n = 81 n = 68 n = 41 n = 108 n = 40
Mean (SD) 47.8 (13.5) 42.7 (15.1) 39.5 (14.2) 34.4 (13.5) 53.3 (9.9) 51.2 (11.5)
p < 0.01a p = n.s.a p = n.s.a
ηp2 = 0.030
VOSP Silhouettes T-score n = 169 n = 70 n = 65 n = 41 n = 104 n = 29
Mean (SD) 49.6 (11.2) 46.5 (11.6) 44.4 (11.0) 42.4 (11.2) 52.9 (10.0) 52.4 (9.3)
p = n.sa p = n.s.a p = n.s.a
Trail Making Test A n = 177 n = 85 n = 68 n = 45 n = 109 n = 40
T-score 45.1 (10.3) 45.4 (10.3) 40.4 (10.2) 41.4 (10.5) 48.0 (9.4) 50.0 (8.2)
Mean (SD) p = n.s.a p = n.s.a p = n.s.a
Trail Making Test B n = 177 n = 85 n = 68 n = 45 n = 109 n = 40
T-score 45.9 (11.1) 42.5 (12.3) 40.3 (11.8) 37.0 (13.0) 49.5 (9.0) 48.7 (7.7)
Mean (SD) p < 0.05a p = n.s.a p = n.s.a
ηp2 = 0.019
Controlled Oral Word n = 176 n = 84 n = 68 n = 44 n = 108 n = 40
Association Test
(COWAT) T-Score
Mean (SD) 49.6 (10.1) 47.5 (10.7) 46.6 (10.0) 44.2 (10.6) 51.5 (9.7) 51.0 (9.7)
p = n.s.a p = n.s.a p = n.s.a
The continuous variables (Age at inclusion, CERAD word list learning and recall T-score, VOSP silhouettes T-score, TMT-A and TMT-B
T-score and COWAT T-score) are summarized by mean (standard deviation, SD). The ordinal variable educational level is described by
median (interquartile range). Variables of assumed normal distribution are compared with one-way ANOVA with predefined contrasts and
effect sizes (ηp2) are provided for significant results (a). Variables of non-normal distribution (MMSE and Clock drawing test) and the ordinal
variable (education level) are compared with Mann-Whitney U tests and effect sizes (r) are provided for significant results (b). The binary
variable sex is described with observed numbers and percentages and compared with Pearson’s Chi square tests (c). Significant p-values and
effect sizes are shown in Bold.
r = 0.188), CERAD word list learning (p < 0.001,
ηp2 = 0.049), CERAD word list recall (p < 0.01,
ηp2 = 0.030), and trail making test B (p < 0.05,
ηp2 = 0.019). However, within the MCI group, this
performance deficit was only shown for the clock
drawing test (p < 0.05, r = 0.186) and CERAD word
list learning (p < 0.01, ηp2 = 0.073). Within the
SCD group we found no significant differences in
cognitive performance between self-referrals and
memory clinic referrals.
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Table 2
Demographic characteristics and cognitive test result comparisons between control group and cognitive symptom group
(SCD and MCI), as well as subgroups with mild cognitive impairment (MCI) and subjective cognitive decline (SCD)
Control Group Cognitive
symptom Group
(MCI & SCD) MCI SCD
Age at inclusion n = 132 n = 299 n = 136 n = 163
Mean (SD) 60.4 (9.3) 63.7 (9.4) 65.4 (9.8) 62.3 (8.9)
p < 0.001a p < 0.001a p = n.s.a
ηp2 = 0.026 ηp2 = 0.064
Female/Total 75/132 155/299 63/136 92/163
Percentage female 56.8% 51.8% 46.3% 56.4%
p = n.s.c p = n.s.c p = n.s.c
Education level n = 131 n = 298 n = 135 n = 163
Median (IQR) 3.0 (2.0) 3.0 (2.0) 3.0 (3.0) 3.0(3.0)
p = n.s.b p = n.s.b p = n.s.b
MMSE n = 131 n = 296 n = 134 n = 162
Mean (SD) 29.4 (0.9) 28.4 (1.7) 27.6 (2.0) 29.1 (1.1)
p < 0.001b p < 0.001b p < 0.05b
r = 0.278 r = 0.514 r = 0.126
Clock Drawing Test n = 130 n = 293 n = 134 n = 159
Mean (SD) 4.9 (0.3) 4.8 (0.5) 4.7 (0.6) 4.9 (0.3)
p < 0.01b p < 0.001b p = n.s.b
r = 0.130 r = 0.250
CERAD word list Learning T score n = 130 n = 293 n = 133 n = 160
Mean (SD) 56.1 (9.5) 47.8 (13.0) 40.9 (12.8) 53.5 (10.2)
p < 0.001a p < 0.001a p < 0.05a
ηp2 = 0.092 ηp2 = 0.313 ηp2 = 0.016
CERAD word list Recall T-score n = 130 n = 289 n = 130 n = 160
Mean (SD) 55.2 (11.2) 46.1 (14.5) 37.5 (14.4) 53.0 (10.3)
p < 0.001a p < 0.001a p = n.s.a
ηp2 = 0.087 ηp2 = 0.320
VOSP Silhouettes T-score n = 120 n = 268 n = 126 n = 142
Mean (SD) 52.7 (8.9) 48.2 (11.2) 43.6 (10.9) 52.3 (9.8)
p < 0.001a p < 0.001a p = n.sa
ηp2 = 0.038 ηp2 = 0.175
Trail Making Test A n = 128 n = 293 n = 132 n = 161
T-score 49.2 (9.6) 45.0(10.2) 40.7 (9.9) 48.6 (8.9)
Mean (SD) p < 0.001a p < 0.001a p = n.s.a
ηp2 = 0.035 ηp2 = 0.157
Trail Making Test B n = 127 n = 293 n = 132 n = 161
T-score 51.6 (8.8) 44.9 (11.7) 39.5 (12.4) 49.4 (9.0)
Mean (SD) p < 0.001a p < 0.001a p < 0.05a
ηp2 = 0.074 ηp2 = 0.243 ηp2 = 0.015




50.5 (7.6) 48.8 (10.4) 45.5 (10.1) 51.6 (9.8)
p = n.s.a p < 0.001a p = n.s.a
ηp2 = 0.072
The continuous variables (Age at inclusion, CERAD word list learning and recall T-score, VOSP silhouettes T-score, TMT-A and
TMT-B T-score and COWAT T-score) are summarized by mean (standard deviation, SD). The ordinal variable educational level
is described by median (interquartile range). Variables of assumed normal distribution are compared with one-way ANOVA
with predefined contrasts and effect sizes (ηp2) are provided for significant results (a). Variables of non-normal distribution
(MMSE and Clock drawing test) and the ordinal variable (education level) are compared with Mann-Whitney U tests and effect
sizes (r) are provided for significant results (b). The binary variable sex is described with observed numbers and percentages
and compared with Pearson’s Chi square tests (c). Significant p-values and effect sizes are shown in Bold.
Cognitive symptom groups compared to control
group
All data pertaining to control and symptom group
comparisons including demographic characteristics
are shown in Table 2.
There were no differences in educational level
or gender distributions between groups. However,
the symptom group was significantly older than
the control group (p < 0.001, ηp2 = 0.026). This dif-
ference was attenuated when comparing the MCI
group to controls (p < 0.001, ηp2 = 0.064), but not
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significant when comparing the SCD group to con-
trols. Moreover, a further analysis of the control
group characteristics showed that a majority was
recruited through the spouses of participants respond-
ing to advertisements (n = 96, 72.7%), whereas 25.8%
(n = 34) were recruited by other means, and only 1.5%
(n = 2) were recruited through the spouses of memory
clinic-referrals.
At symptom group level, including both MCI and
SCD participants, we found significantly reduced
test performances compared to controls on all mea-
sures (p < 0.01), except the controlled oral word
association test (COWAT). When comparing con-
trols to MCI participants, significant reductions were
found for all measures, including COWAT (p < 0.001,
see Table 2 for details). SCD participants per-
formed significantly worse compared to controls on
MMSE (p < 0.05, r = 0.126), CERAD word list learn-
ing (p < 0.05, ηp2 = 0.016), and trail making test B
(p < 0.05, ηp2 = 0.015).
DISCUSSION
In agreement with our hypothesis, memory clinic-
referrals performed worse on cognitive tests than
self-referred individuals. In addition, they were both
younger and less educated compared to self-referrals.
However, when comparing the MCI and SCD groups
separately, only the MCI group showed these recruit-
ment biases. We found no differences in cognitive
performance or demographic characteristics between
recruitment strategies within the SCD group. Further,
we found that the SCD group performed worse on
both cognitive screening (MMSE), and the cognitive
subtests; word list learning (CERAD), and divided
attention (TMT-B) compared to an age and education
matched control group. In addition, the MCI group
was shown to be older compared to controls, but did
not differ in gender distributions or educational level.
In line with earlier reports, our findings show
that including at-risk patients from memory clinics
preferentially recruit individuals who are more cogni-
tively impaired compared to self-referred individuals
from the community. These findings generally sup-
port the notion that inclusion from memory clinics
recruit individuals that are at higher risk of conver-
sion to dementia [16, 17] or are farther along the
disease trajectory than participants recruited through
other means [14, 15]. Moreover, the MCI partici-
pants recruited through memory clinics, while more
cognitively impaired, were also younger and might
represent an earlier onset, or more aggressive form of
pathology than found in the older self-referred sam-
ple. Memory clinic samples have shown to harbor
higher risk in terms of genetic risk factors [15], higher
presence of AD-type pathology [38], or more aggres-
sive forms of pathology [14]. However, the memory
clinic-referred MCI cases in our sample had a lower
educational level than their self-referred counter-
parts. Educational level is associated with cognitive
reserve [39], thus lower cognitive performance in this
group may be confounded with a lesser ability to
compensate for brain pathology compared to the self-
referred group. Lastly, our control group comprised
nearly 73% advertisement recruited individuals. It
has been shown that controls recruited from conve-
nience samples tend to be younger, better educated,
and perform better on cognitive tests than controls
recruited through population samples [15]. As such,
our control group may not be an adequate compar-
ison to memory clinic-referrals. However, although
the cognitive symptom group was found to be older
than controls, no difference was found in educational
levels. Moreover, apart from the clock drawing test
and MMSE, cognitive test scores were adjusted for
effects of age and educational levels making between
group comparisons possible.
We found no significant differences in either demo-
graphics or cognitive performance due to recruitment
bias within the SCD group. This is perhaps not sur-
prising given the fact that a core criterion for SCD
is normal range of scores on neuropsychological
examinations [6]. Any subtle differences between
recruitment methods may be too small for detection
within this group. Furthermore, recruitment did not
bias other key demographics, leaving self- and mem-
ory clinic-referrals matched on these variables. To
our knowledge, only one study to date have shown
recruitmentsource topreferentiallybiascognitiveper-
formance in SCD cases [21]. However, there are key
differences in sample characteristics between stud-
ies. While both studies recruited participants from
memory clinics, Abdelnour et al. [21] recruited par-
ticipants from an open house initiative (OHI). This
initiative offered free examinations to the community
and did not specifically recruit participants to a mem-
ory study. In addition, the OHI SCD cases were more
likely to be female and had higher educational lev-
els compared to the memory unit sample. Conversely,
regardless of recruitment source, participants within
the DDI cohort were recruited specifically for a study
on cognitive reduction. Moreover, we found no sig-
nificant recruitment bias in demographics within the
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SCD group. Thus, regardless of recruitment source,
the DDI SCD participants may be more similar within
the DDI cohort, and thereby showing similar levels of
cognitiveperformances.However,althoughnotreach-
ing the level of statistical significance, the data did
show a trend towards both subtle lower performance
and lower educational level in memory clinic-referred
SCD cases compared to self-referrals. The lack of sta-
tistical significance for this result may be due to a
small sample size (memory clinic-referred SCD cases
(n = 40)), and could have reached statistical signifi-
cance given a larger sample. Moreover, we did find an
overallsignificantdifferenceincognitiveperformance
at symptom group level beyond what was shown by
the MCI group alone. This suggests that although the
differences are small, SCD cases recruited from mem-
ory clinics may represent a cognitively more impaired
group than self-referred SCD cases.
While recruitment source did not significantly bias
cognitive performance or demographics, we observed
a relative increase in depressive symptoms measured
by the GDS 15 in the memory clinic-referred SCD
cases compared to self-referrals (data not shown).
However, the observed increase in symptoms was not
above the suggested cut-offs for clinical depression
at group level [40]. This is not a surprising find-
ing since severe psychiatric illness, including major
depression, is a core exclusion criterion in this study.
However, this may not be the case in all study designs
investigating SCD cases. As such, recruitment from
memory clinics may lead to inclusion of a higher per-
centage of clinically depressed individuals. The role
of depressive symptoms in SCD and preclinical AD is
however unclear [12]. A recent study by Perrotin et al.
[20] comparing SCD cases recruited from memory
clinics and community sample, showed significant
reductions in gray matter volumes related to AD
pathology in the memory clinic group. The authors
conclude that medical help seeking and increased
depressive symptoms were related to these volume
reductions and pointing out increased affective bur-
den as a potential part of prodromal AD. Conversely,
Heser et al. [41] found that depressive symptoms
were fully mediated by subjective memory impair-
ment worry, suggesting that depressive symptoms
were caused by an increased awareness of subjective
decline, explaining levels of depressive symptoms in
individuals with subjective cognitive complaints. As
such, depressive symptoms even at subclinical levels
may be an important factor in preclinical AD. This
should be further explored in future studies focusing
on the trajectory of preclinical AD development.
While not demonstrating statistically significant
recruitment bias in cognitive performance, the
present study shows that the SCD group performed
worse on key cognitive domains associated with AD
such as learning and executive functions, as well as
a general decline in overall cognitive screening per-
formance (MMSE) compared to controls. Although
observed effect sizes were small, these findings sup-
port the notion that SCD could be a symptom of
awareness of subtle cognitive decline witnessed by
small declines in cognitive performance, while still
performing within limits of normal variations [6]. A
recent review by Garcia-Ptacek et al. [42] summarizes
that, although most studies show poorer cognitive
performance in persons with subjective cognitive
complaints, such findings have not been univer-
sally supported. Furthermore, reductions within these
domains may be influenced by other factors such
as personality, anxiety or depressive symptoms, or
accounted for by other medical or neurological disor-
ders other than AD. Both CERAD word list learning
and Trail making test B rely on adequate working
memory and attentional processes, both of which can
be affected by numerous conditions. Also, the SCD
group did not perform worse than controls on memory
recall. These findings are therefore not unequivocally
linked to AD-pathology and may represent different
conditions or disease etiologies. Moreover, the con-
trol and SCD group performed very similar in most
of the cognitive measures, which may suggest that
AD enrichment within the SCD group is relatively
low. Future studies combining biological markers
with SCD phenotypes and follow-ups are needed to
ascertain the meaning of this finding.
The present study has some limitations that need to
be addressed. First, due to geographic differences in
Norway, the availability of memory clinics may dif-
fer. This could lead to a biased inclusion of memory
clinic-referrals living in, or near city centers where the
university hospitals are located. Second, our study is
limited to a cross sectional comparison of cohort char-
acteristics and does not include outcome measure of
disease progression. Third, we did not include the use
of biomarker evidence to further characterize selec-
tion bias, limiting interpretation of current findings.
Fourth, the inclusion criteria allow the recruitment of
younger middle aged adults (40–80 y), which lowers
the mean age and increases variability in our sam-
ple. Advancing age is a well-known risk factor for
AD. Thus, while this is an optimal design to cap-
ture early preclinical disease events in a longitudinal
study, it may lead to dilution of AD prevalence in
B.-E. Kirsebom et al. / Recruitment Bias in Preclinical AD 1629
both SCD and MCI samples in our cross-sectional
analysis. Lastly, an important note has to be made
on the use of Sotaniemi et al. [34] CERAD word
list normative dataset. These norms are based on a
sample that is on average 10 years older and less edu-
cated than the DDI cohort. This may in some cases
lead to uncertain classification of MCI and SCD. As
such, there may be a need to establish normative
datasets better suited for younger pre-clinical at-risk
cohorts.
A central aim of the DDI project is to examine
incipient disease activity to detect and track dementia
disease progression in its preclinical states. There-
fore, the cohort is comprised of a younger sample
than most previous large cohort studies and the char-
acteristics of this sample with regard to the impact of
biomarker findings and longitudinal outcomes are not
yet known. Future studies on the DDI cohort employ-
ing longitudinal designs and utilizing both biological
and psychological data will serve to further delineate
the clinical significance of these findings to define the
characteristics of SCD due to AD more closely.
Conclusions
Our findings indicate that recruitment through
memory clinics preferentially includes participants
at higher risk of dementia, or are more advanced
than cases recruited through other means. In addi-
tion, SCD cases were shown to perform worse on key
cognitive measures compared to controls and may
suggest that SCD is a symptom of subtle cognitive
decline. Recruitment was not shown to significantly
bias demographic characteristics or cognitive per-
formance within the SCD group alone. However, at
symptom group level, we did find an overall sig-
nificant effect of worse cognitive performance in
memory clinic-referrals beyond what was shown by
the MCI group alone. This suggests that although the
differences in cognitive performance are small, SCD
cases recruited from memory clinics may represent
a cognitively more impaired group than self-referred
SCD cases. These findings suggest that recruitment
source affects clinical characteristics of preclinical
cohorts and should be taken into consideration when
comparing findings between studies utilizing differ-
ent recruitment methods. Future studies employing
longitudinal designs and combining psychological
and biological data are needed to further delineate
the significance of these findings, as well as address-
ing the impact of recruitment bias on biological
risk-factors within the DDI cohort.
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